Canada markets closed

Seres Therapeutics, Inc. (1S9.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
1.2620-0.0020 (-0.16%)
At close: 03:53PM CEST

Seres Therapeutics, Inc.

101 Cambridgepark Drive
Cambridge, MA 02140
United States
617 945 9626
https://www.serestherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees233

Key Executives

NameTitlePayExercisedYear Born
Mr. Eric D. Shaff M.B.A.President, CEO & Director939.03kN/A1976
Dr. Lisa von Moltke M.D.Executive VP & Chief Medical Officer665.17kN/A1959
Dr. Teresa L. Young Ph.D., R.Ph.Executive VP and Chief Commercial & Strategy Officer556.18kN/A1967
Ms. Marella ThorellExecutive VP & CFON/AN/A1967
Dr. David S. Ege Ph.D.Executive VP & Chief Technology Officer130.9kN/A1975
Dr. Matthew R. Henn Ph.D.Executive VP & Chief Scientific Officer590.58kN/A1975
Mr. Carlo Tanzi Ph.D.Investor Relations OfficerN/AN/AN/A
Mr. Thomas J. DesRosier Esq., J.D.Chief Legal Officer, Executive VP & Secretary660.03kN/A1955
Ms. Caroline HoldaAssistant General CounselN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Seres Therapeutics, Inc.’s ISS Governance QualityScore as of July 1, 2024 is 8. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.